Coral Laboratories Ltd (CORALAB) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Coral Laboratories Ltd on NSE and BSE, with an AI summary of each filing.
Coral Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2026 ,inter alia, to consider and approve Pursuant to Regulation 29 ....
Intimation · 14 Nov 2026, 5:30 am
Coral Laboratories Board to Consider Q2 Results on 14th Nov'26 Coral Laboratories Ltd has scheduled a Board of Directors meeting on 14th Nov'26 to consider and approve the standalone unaudited financial results for the quarter and half-year ended 30th Sep'26. Per insider trading regulations, the trading window for dealing in the company's equity shares commenced closure on 1st Oct'26 and will remain shut until 48 hours following the declaration of the financial results.
Voting Results and Scrutinizer Report for AGM held on September 30, 2026
Annual General Meeting · 30 Sept 2026, 5:00 pm
Proceedings of the 44th Annual General Meeting of the Company held on Tuesday, 29th September 2026
Annual General Meeting · 29 Sept 2026, 6:39 pm
Considered and approved Cost Audit Report in CRA-3 for the financial year 2025-26
Outcome · 25 Sept 2026, 8:30 pm
Coral Laboratories Board Approves FY26 Cost Audit Report Coral Laboratories Limited informed stock exchanges that its Board of Directors met on 25th Sep'26 and considered and approved the Cost Audit Report in Form CRA-3 for FY26. The meeting commenced at 02:30 p.m. and concluded at 02:58 p.m. No other material business transactions or strategic updates were disclosed.
Coral Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/09/2026 ,inter alia, to consider and approve Intimation of Board meeting ....
Intimation · 21 Sept 2026, 5:05 pm
Coral Laboratories Schedules Board Meeting for FY26 Cost Audit Report Approval Coral Laboratories has scheduled a meeting of its Board of Directors on 25th Sep'26. Under Regulation 29 of SEBI Listing Regulations, the board will convene primarily to consider and approve the Cost Audit report for the financial year 2025-26, alongside other general business matters subject to the chairman's approval.
Annual report for the financial year 2025-26
Others (Uncategorized) · 04 Sept 2026, 7:23 pm
Notice of 44th AGM scheduled to be held on September 29, 2026.
Annual General Meeting · 04 Sept 2026, 7:15 pm
Intimation for holding 44th AGM
Annual General Meeting · 14 Aug 2026, 11:46 pm
Financial results for the quarter ended on June 30, 2026
Financial Result · 14 Aug 2026, 11:43 pm
Record date for final dividend and Book Closure date
Dividend · 14 Aug 2026, 11:36 pm
Coral Laboratories Sets Record Date for Final Dividend and AGM Coral Laboratories Ltd has announced its 44th Annual General Meeting (AGM) will be held on Sep 29, '26. The company has fixed Sep 22, '26 as the record date to determine shareholder eligibility for the final dividend. The register of members will be closed from Sep 23, '26 to Sep 29, '26, inclusive, for the purpose of the AGM and dividend payment. The meeting will be conducted via video conferencing.
Outcome of Board meeting
Outcome · 14 Aug 2026, 11:27 pm
Coral Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 ,inter alia, to consider and approve 1. Standalone unaudited ....
Intimation · 14 Aug 2026, 5:30 am
Clarification with respect to query raised by BSE for movement in price
Others (Uncategorized) · 25 Jun 2026, 8:25 pm
Coral Laboratories Clarifies Significant Stock Price Movement In response to a BSE query on 24 Jun'26, Coral Laboratories Ltd stated on 25 Jun'26 that the recent significant movement in its stock price is purely market-driven. The management affirmed it has no control over, nor any knowledge of the specific reasons behind the price volatility. The company confirmed it is compliant with all SEBI disclosure requirements under Regulation 30 and has no undisclosed material information to report that could be influencing the stock's performance.
The Exchange has sought clarification from Coral Laboratories Ltd on June 24, 2026 with reference to significant movement in price, in order to ensure that investors have latest relevant ....
Others (Uncategorized) · 24 Jun 2026, 10:58 pm
Outcome of Board meeting
Outcome · 18 Jun 2026, 6:09 pm
Coral Laboratories Board Approves Remuneration Increase Proposal Coral Laboratories' board, in a meeting on 18 Jun'26, approved a proposal to increase the remuneration for Ms. Meera Doshi. The company will now seek shareholder approval for this resolution via a postal ballot notice. The specific financial details of the proposed increase were not disclosed in the filing.
Outcome of Board Meeting
Others (Uncategorized) · 18 Jun 2026, 6:05 pm
Coral Laboratories Board Approves Key Remuneration Increase Coral Laboratories' board, in its meeting on 18 Jun'26, approved a proposal to increase the remuneration for Ms. Meera Doshi. The company will now seek shareholder approval for this resolution via a postal ballot. This decision could impact the company's employee expenses and overall profitability. The meeting commenced at 11:45 a.m. and concluded at 12:30 p.m. on the same day. The specifics of the remuneration hike were not disclosed in the filing.
Final dividend of ? 2 per share
Dividend · 31 May 2026, 1:13 am
Coral Laboratories Board Recommends Final Dividend for FY26 Coral Laboratories' Board of Directors recommended a final dividend for the financial year 2025-26 at its meeting on 30 May'26. The proposed dividend is ₹2.00 per share on a face value of ₹10 each, representing a 20% payout. This dividend is subject to shareholder approval at the upcoming Annual General Meeting.
Appointment of Cost Auditor
Change in Auditor · 31 May 2026, 1:04 am
Coral Laboratories Appoints New Cost Auditor for FY27 Coral Laboratories Ltd. (Scrip Code: 524506) announced the appointment of M/s Aatish Dhatrak & Associates (FRN: 101575) as its new Cost Auditor. The appointment, recommended by the Audit Committee and approved by the Board of Directors on 30 May'26, is for the financial year 2026-2027. The appointed firm has expertise in cost audit, risk management, and related services, and is not related to any directors of the company.
Appointment of Internal Auditor
Change in Auditor · 31 May 2026, 1:03 am
Coral Laboratories Appoints M/s. S K Doshi & Associates as Internal Auditor Coral Laboratories Ltd. appointed M/s. S K Doshi & Associates, Chartered Accountants, as its new Internal Auditor for the financial year 2026-2027. The appointment, recommended by the Audit Committee, was approved by the Board of Directors on 30 May'26. The newly appointed firm was established in 1986 and has extensive expertise in internal audits, accounts, and taxation. The company has confirmed that the appointed auditor has no relationship with any of its directors.
The Board has approved ? 2 per share dividend.
Dividend · 31 May 2026, 12:58 am
Coral Labs Q4FY26 PAT Rises; Board Recommends ₹2.00 Dividend Coral Laboratories reported a Q4FY26 PAT of ₹522.39 lakhs, an 88.2% QoQ increase from ₹277.55 lakhs and an 84.8% YoY increase from ₹282.71 lakhs. Revenue from operations for the quarter stood at ₹2,647.93 lakhs. For the full year FY26, PAT was ₹1,638.13 lakhs, a 32.2% YoY decline, on revenues of ₹8,589.97 lakhs. The Board recommended a final dividend of ₹2.00 per share (20%) for FY26. Additionally, new Internal and Cost Auditors were appointed for FY27.
Results for the financial year ended on March 31, 2026
Financial Result · 31 May 2026, 12:56 am
Coral Laboratories Q4FY26 Results and FY26 Dividend Announcement For Q4FY26, Coral Laboratories reported a profit of ₹522.39 lakhs, an 88% QoQ increase and 85% YoY increase. Revenue from operations was ₹2,647.93 lakhs, up 23% QoQ but down 6% YoY. For FY26, net profit was ₹1,638.13 lakhs, a 32% YoY decline, on revenue of ₹8,589.97 lakhs, down 25% YoY. The Board recommended a final dividend of ₹2.00 per share (20%) for FY26. Additionally, new internal and cost auditors were appointed for FY27.
Outcome of Board meeting held on May 30, 2026
Outcome · 31 May 2026, 12:51 am
Coral Laboratories Ltd - Financial Result for the Quarter ended 31st Mar'26 (Standalone, INR Lakhs) ■ Revenue: 2,648 (-5.9% YoY | +22.8% QoQ) ■ EBITDA: 620 (+131.0% YoY | +228.1% QoQ) ■ EBITDA Margin (%): 23.4 (+1388 bps YoY | +1466 bps QoQ) ■ PAT: 522 (+84.8% YoY | +88.2% QoQ) ■ EPS (INR): 14.6 (+84.8% YoY | +88.2% QoQ)
Board to consider Dividend
Dividend · 20 May 2026, 7:03 pm
Coral Laboratories Board Meeting to Consider FY26 Results and Dividend Coral Laboratories has scheduled a Board Meeting on May 30, '26, to approve audited financial results for the quarter and year ended Mar 31, '26. Key agenda items include the recommendation of a final dividend for FY26 and the appointment of internal and cost auditors for FY27. The trading window for insiders has been closed since Apr 1, '26, and will reopen 48 hours after the results are declared.
Coral Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2026 ,inter alia, to consider and approve Pursuant to Regulation 29 ....
Intimation · 30 May 2026, 5:30 am
Coral Laboratories Board Meeting Scheduled for May 30, 2026, to Discuss FY26 Results Coral Laboratories has scheduled a Board of Directors meeting for May 30, '26, to approve the standalone audited financial results for the quarter and year ended Mar 31, '26. The board will also consider the recommendation of a final dividend for FY26. Other agenda items include the appointment of an internal auditor and a cost auditor for the financial year 2026-27. The trading window for insiders has been closed since Apr 1, '26, and will reopen 48 hours after the results are declared.
<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
Others (Uncategorized) · 30 Apr 2026, 6:58 pm
Coral Laboratories Not Classified as a Large Corporate Under SEBI Framework Coral Laboratories Ltd informed exchanges on 23rd Apr'26 that it does not fall under the 'Large Corporate' category as defined by SEBI's circular dated 26th Nov'18. Consequently, the mandatory fundraising framework requirements are not applicable to the company. The disclosure, as of 31st Mar'26, confirms nil outstanding long-term borrowings (excluding ECB). As the criteria are not met, details regarding credit ratings and other related framework compliances are not applicable. This clarification exempts the company from specific debt market borrowing obligations.